India's drug regulator inspected 90% of cough syrup makers, found lapses in some, official says (Feb 23)

India's drug regulatory authority has conducted inspections of approximately 90% of the country's cough syrup manufacturers, revealing several regulatory breaches among some firms. This initiative comes in the wake of heightened scrutiny following safety concerns related to cough syrups that have been implicated in serious health issues, including fatalities in various regions. The inspections aimed to ensure compliance with safety and quality standards, reflecting the government's commitment to safeguarding public health. Officials noted that while many manufacturers adhered to regulatory norms, a significant number exhibited lapses that could compromise product safety. The findings underscore the necessity for stringent oversight in the pharmaceutical sector, particularly in light of rising cases of counterfeit and substandard medications. As the health ministry continues to prioritize drug safety, these inspections are expected to lead to more robust regulatory frameworks to protect consumers across India.